References
- Koene H R, Kleijer M, Algra J, et al. Fc γRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell Fc γRIIIa, independently of the Fc γRIIIa-48L/R/H phenotype. Blood 1997; 90: 1109–1114
- Wu J, Edberg J C, Redecha P B, et al. A novel polymorphism of FcγRIIIa (CD16) alters receptor function and predisposes to autoimmune disease. J Clin Invest 1997; 100: 1059–1070
- Cartron G, Dacheux L, Salles G, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene. Blood 2002; 99: 754–758
- Weng W K, Levy R. Two immunoglobulin G fragment C receptor polymorphisms independently predict response to rituximab in patients with follicular lymphoma. J Clin Oncol 2003; 21: 3940–3947
- Treon S P, Hansen M, Branagan A R, et al. Polymorphisms in FcγRIIIA (CD16) receptor expression are associated with clinical response to rituximab in Waldenström's macroglobulinemia. J Clin Oncol 2005; 23: 474–481
- Musolino A, Naldi N, Bortesi B, et al. Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. J Clin Oncol 2008; 26: 1789–1796
- Bibeau F, Crapez E, Di Fiore F, et al. Association of FcγRIIa and FcγRIIIa polymorphisms with clinical outcome in metastatic colorectal cancer patients (mCRC) treated with cetuximab and irinotecan. J Clin Oncol 2009; 27: 1122–1129
- Shields R L, Namenuk A K, Hong K, et al. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII, and FcRn and design of IgG1 variants with improved binding to the FcγR. J Biol Chem 2001; 276: 6591–6604
- Shields R L, Lai Keck R, et al. Lack of fucose on human IgG1 N-linked oligosaccharide improves binding to human Fcγ RIII and antibody-dependent cellular toxicity. J Biol Chem 2002; 277: 26733–26740
- Okazaki A, Shoji-Hosaka E, Nakamura K, et al. Fucose depletion from human IgG1 oligosaccharide enhances binding enthalpy and association rate between IgG1 and FcγRIIIa. J Mol Biol 2004; 336: 1239–1249
- Salles G, Morschhauser F, Cartron G, et al. A phase I/II study of ro5072759 (GA101) in patients with relapsed/refractory CD20+ malignant disease. Blood 2008; 112: 234
- Cartron G, Lamy T, Morschhauser F, et al. Phase I study of RO5072759 (GA101) in relapsed/refractory chronic lymphocytic leukemia. Haematologica 2009; 94: 201
- Zhang W, Gordon M, Schultheis A M, et al. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 2007; 25: 3712–3718
- Lejeune J, Thibault G, Ternant D, et al. Evidence for linkage disequilibrium between Fcγ RIIIa-V158F and Fcγ RIIa-H131R polymorphisms in white patients, and for an Fcγ RIIIa-restricted influence on the response to therapeutic antibodies. J Clin Oncol 2008; 33: 5489–5491
- Hatjiharissi E, Xu L, Santos D D, et al. Increased natural killer cell expression of CD16, augmented binding and ADCC activity to rituximab among individuals expressing the Fc{γ}RIIIa-158 V/V and V/F polymorphism. Blood 2007; 110: 2561–2564
- Congy-Jolivet N, Bolzec A, Ternant D, et al. Fc γ RIIIa expression is not increased on natural killer cells expressing the Fc γ RIIIa-158V allotype. Cancer Res 2008; 68: 976–980
- Dall'Ozzo S, Tartas S, Paintaud G, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration–effect relationship. Cancer Res 2004; 64: 4664–4669
- Weng W-K, Levy R. Immunoglobulin G Fc receptor polymorphisms do not correlate with response to chemotherapy or clinical course in patients with follicular lymphoma. Leuk Lymphoma 2009; 50: 1494–1500